Quintiles, Movetis In Commercialization Pact

Quintiles has entered into a strategic alliance with Movetis NV for the commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany. Under the alliance, Quintiles will be responsible for commercialization, consulting, marketing services, regulatory and post-marketing pharmacovigilance.

Movetis is a European specialty pharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of gastrointestinal diseases. Movetis obtained approval for Resolor in Europe for the symptomatic treatment of chronic constipation for women when laxatives are inadequate.

Chris Pepler, senior vice president of Global Business Development and Operations for Quintiles said: “This agreement is an example of how leading specialty pharma companies are building partnerships that extend beyond the traditional Commercial Sales Organization model to manage risk, increase productivity, overcome complexity and demonstrate value to stakeholders in the New Health. We are pleased that Movetis has chosen to leverage Quintiles’ suite of comprehensive services, including our product and brand solutions, to help ensure the commercial success of Resolor.”

Movetis chief executive officer Dirk Reyn said: “We are confident that our alliance with Quintiles will help drive our goal of becoming a successful European specialty GI company. The launch of Resolor will be a key milestone as we continue to build on our expertise in bringing new GI drugs from discovery to marketing.”